KPC Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People's Republic of China and internationally. It offers artemether, panax notoginseng, and gastrodine series drugs, as well as Chinese medicines and ethnic drugs under the Luotai, Tianxuanqing, Artemedine, Artem, and Arco brand names for treating cardio-cerebral-vascular and nervous system diseases, as well as malaria. The company also provides Dai medicines; antibiotics, chemical medicinal raw materials, chemical pharmaceutical preparations, traditional Chinese medicinal materials, biological products, biochemical drugs, and health foods; Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, and Ribavirin spray products; glycyrrhizic acid; and GLP-1, a long-acting hypoglycemic drug. It markets artemisinin antimalarials, generic drugs, and medical apparatus. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals, Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.

KPC Pharmaceuticals, Inc.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc.

KPC Pharmaceuticals is a Chinese pharmaceutical company that manufactures and develops pharmaceutical products with a focus on international markets.

KPC Pharmaceuticals

KPC Pharmaceuticals, Inc 昆药集团股份有限公司 | 214 followers on LinkedIn. KPC is a pharmaceutical company which focused on innovative natural botanical drugs. | KPC Pharmaceuticals, Inc (hereinafter be abbreviated as ‘KPC’, 600422 SH) was established in March 1951 and floated on the Shanghai Stock Exchange in December 2000. With its considerable professional experience in pharmaceutical industry, the company is listed as one of the new key national high-tech companies and one of the Top 100 companies in the Chinese medical industry. The company’s brands such as Luotai®, Tianxuanqing®, Artemedine®, Artem® and Arco® currently enjoy a good reputation both at home and abroad.

Metric
Company Name	KPC Pharmaceuticals, Inc.	CanSino Biologics Inc.
Symbol	600.42K	6.18K
MSH ID	CN:COM:KPC	COM:CANSINOTECH
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Drug Manufacturers - Specialty & Generic	Drug Manufacturers - Specialty & Generic
Country	CN	CN
Stage
Employee Count	5.05K	1.49K
Website	kpc.com.cn	cansinotech.com
LinkedIn	kpcpharma	cansino-biotechnology-inc.
Founders

Metric
Market Cap	1.75B	833.96M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	1.05B	49.12M
Revenue (LTM)
Revenue (NTM)
Gross Profit	451.58M	-61.04M
EBITDA	94.20M	-203.86M
Operating Income	64.82M	-236.92M
Net Income	61.16M	-203.94M
EPS	0.08	-0.83
Diluted EPS	0.08	-0.83
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.43	0.14
Operating Profit Margin	0.07	-0.86
EBITDA Margin	0.09	-4.15
Net Profit Margin	0.06	-1.42
Return on Equity	0.08	-0.16
Return on Assets	0.04	-0.11
Return on Capital Employed	0.09	-0.08

6004

CN:COM:KPC

KPC Pharmaceuticals

Last Close

14.46

25/11 07:00

Market Cap

12.73B

Beta: -

Volume Today

9.73M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	33.73
P/B Ratio	2.51
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.37	20.35
EV Multiple	28.77	-3.00

Metric
Days Sales Outstanding	157.97	485.87
Days Payables Outstanding	75.02	170.20
Days Inventory Outstanding	151.53	251.49
Operating Cycle	314.60	815.83
Cash Conversion Cycle	254.34	770.86
Asset Turnover	0.83	0.07

Metric
Operating Cash Flow	50.02M	-124.92M
Free Cash Flow	41.01M	-208.89M
Cash Flow to Debt	0.79	-0.12
Operating Cash Flow/Sales	0.11	-0.43
Free Cash Flow Yield	0.04	-0.25

Metric
Cash & Equivalents	205.36M	388.10M
Accounts Receivable	-19.10M	36.58M
Inventory	232.21M	48.53M
Goodwill	12.62M
Debt to Capitalization	0.19	0.34
Debt to Assets	0.09	0.21
Current Ratio	1.94	2.24
Quick Ratio	1.46	2.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.01	1.04
SG&A to Revenue	0.01	0.34